儿童ALL异基因移植后复发呈现高度个体化克隆演化及可靶向突变
该研究对10例儿童急性淋巴细胞白血病(ALL)异基因造血干细胞移植(allo-SCT)后复发患者的白血病细胞进行全外显子测序,旨在刻画突变图谱并识别可靶向突变。结果显示移植后复发呈现高度患者个体化遗传学改变和显著克隆动态,仅少数改变持续存在;10例中4例检出TP53突变,9例存在可用靶向药物的基因改变,2例TP53突变者体外可被APR-246有效靶向。
要点
- 移植后ALL复发突变谱高度个体化,克隆动态显著
- 硫嘌呤耐药相关NT5C2突变在解除维持化疗选择压力后消失
- 10例中9例存在可靶向基因改变,提示个体化靶向治疗潜力
核心结论
- 儿童ALL异基因移植后复发呈现高度个体化遗传学改变和显著克隆动态,多数复发携带可靶向突变。
研究设计与样本
- 对10例儿童ALL异基因造血干细胞移植后复发患者的白血病原始细胞进行全外显子测序。
主要发现
- 移植后ALL复发显示高度多样且多为患者个体化的遗传学改变。
- 从初诊到移植后复发的突变克隆分析显示显著克隆动态,仅极少数改变持续存在。
- 3例首次复发检出介导硫嘌呤耐药的NT5C2突变,在移植后复发时因维持化疗选择压力解除而消失。
- 10例中4例在移植后检出TP53突变,反映既往抗肿瘤治疗选择压力相关的获得性化疗耐药。
- 10例中9例移植后复发存在可用新型靶向药物的基因改变,2例TP53突变者的白血病原始细胞可被APR-246有效靶向。
临床怎么用
- 对移植后复发的儿童ALL可行全外显子测序以识别可靶向突变,为个体化治疗提供依据。
局限性
- 样本量仅10例,结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival of patients with pediatric acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (allo-SCT) is mainly compromised by leukemia relapse, carrying dismal prognosis. As novel individualized therapeutic approaches are urgently needed, we performed whole-exome sequencing of leukemic blasts of 10 children with post-allo-SCT relapses with the aim of thoroughly characterizing the mutational landscape and identifying druggable mutations. We found that post-allo-SCT ALL relapses display highly diverse and mostly patient-individual genetic lesions. Moreover, mutational cluster analysis showed substantial clonal dynamics during leukemia progression from initial diagnosis to relapse after allo-SCT. Only very few alterations stayed constant over time. This dynamic clonality was exemplified by the detection of thiopurine resistance-mediating mutations in the nucleotidase NT5C2 in 3 patients' first relapses, which disappeared in the post-allo-SCT relapses on relief of selective pressure of maintenance chemotherapy. Moreover, we identified TP53 mutations in 4 of 10 patients after allo-SCT, reflecting acquired chemoresistance associated with selective pressure of prior antineoplastic treatment. Finally, in 9 of 10 children's post-allo-SCT relapse, we found alterations in genes for which targeted therapies with novel agents are readily available. We could show efficient targeting of leukemic blasts by APR-246 in 2 patients carrying TP53 mutations. Our findings shed light on the genetic basis of post-allo-SCT relapse and may pave the way for unraveling novel therapeutic strategies in this challenging situation.
引用
- Hoell JI, Ginzel S, Kuhlen M, et al. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood Adv. 2019. PMID: 31648313. doi:10.1182/bloodadvances.2019000051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。